Historically, modeling of infectious diseases has been conducted in discrete silos wherein the pharmacology of treatments, epidemiology of outbreaks, and health economic impacts were not linked. Consequently, inappropriate assumptions have been made about adjacent disciplines. In addition, for today’s drug developer, regulatory success alone is not enough. Increasingly, pharmaceutical companies must justify the pricing of medicines to society and payer.
A pharma client wanted to know if it was possible to quantify the societal impact of a new dose regimen or novel candidate against an emerging pandemic influenza strain. Read this case study to learn how Certara led and managed execution of developing a “pharmacology to payer” framework that linked pharmacology of treatments, epidemiology of outbreaks, and their health economic impacts.